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expression of reelin-mRNA of 29.1% in the white (p = 0.022) 
and 13.6% in the gray matter (p = 0.007) compared to the 
control group. None of the other regions examined showed 
any statistically significant differences. Conclusion: Since 
reelin is responsible for migration and synapse formation, 
the decreased gene expression of reelin in the left prefrontal 
area of schizophrenia patients points to neurodevelopmen-
tal deficits in neuronal migration and synaptic plasticity. 
However, our study group was small, and results should be 
verified using larger samples.  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Schizophrenia is a complex neurodevelopmental dis-
order, where susceptibility genes and environmental fac-
tors are assumed to play a role in the pathophysiology of 
the disease via abnormal connectivity in neuronal net-
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 Abstract 
 Background: Reelin is under epigenetic control and has 
been reported to be decreased in cortical regions in schizo-
phrenia. Methods: To establish if expression of reelin is al-
tered in specific cortical, hippocampal or thalamic regions of 
schizophrenia patients, we measured gene expression of 
reelin in a postmortem study of elderly patients with schizo-
phrenia and non-affected controls in both hemispheres dif-
ferentiating between gray and white matter. We compared 
cerebral postmortem samples (dorsolateral prefrontal cor-
tex BA9 and BA46, superior temporal cortex BA22, entorhinal 
cortex BA28, sensoric cortex BA1–3, hippocampus, CA4, me-
diodorsal nucleus of the thalamus) from 12 schizophrenia 
patients with 13 normal subjects investigating gene expres-
sion of reelin in the gray and white matter of both hemi-
spheres by in situ-hybridization. Results: The left prefrontal 
area (BA9) of schizophrenia patients revealed a decreased 
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works  [1] . In addition to a number of risk genes, genome-
wide association studies revealed an association of reelin 
risk genes with schizophrenia specifically in women  [2–
4] . In addition, reelin is under epigenetic controls, and 
hypermethylation of the reelin promoter has been shown 
in schizophrenia  [5, 6] .
 Reelin is a glycoprotein which controls neuronal mi-
gration and synaptic plasticity, suggesting that neurode-
velopmental disturbances in schizophrenia are related 
to its dysfunction  [7] . In schizophrenia, reelin expres-
sion has been reported to be decreased in prefrontal and 
temporal cortex, hippocampus, caudate nucleus and 
cerebellum  [8–13] , but results in the prefrontal cortex 
and hippocampus have not been consistent  [14] . On the 
cellular level, interstitial white matter neurons expressed 
lower levels of reelin in the dorsolateral prefrontal cor-
tex (DLPFC), superior temporal cortex and hippocam-
pus as well as layer I neurons and interneurons of the 
DLPFC  [15, 16] . Therefore, we hypothesized decreased 
reelin expression in the DLPFC and investigated its 
mRNA level in several human brain regions of schizo-
phrenia patients and healthy controls by in situ hybrid-
ization, distinguishing between cortical gray and white 
matter.
 Materials and Methods 
 Human Postmortem Tissue 
 We collected postmortem brain samples from patients with 
DSM-IV residual schizophrenia (n = 12) who had been diagnosed 
using the DSM-IV checklist of the American Psychiatric Associa-
tion and elderly comparison subjects (n = 13). All schizophrenia 
patients had been long-term inpatients at the Mental State Hospital 
Wiesloch, Germany, and had been diagnosed ante-mortem accord-
ing to DSM-IV criteria  [17] . For each patient, the history of antipsy-
chotic treatment was assessed by examining the medical charts. We 
then calculated the last dose as well as the cumulative dose during 
the last 10 years of antipsychotic medication in chlorpromazine 
equivalents (CPE) through the algorithm developed by Jahn and 
Mussgay  [18] .  Table 1 outlines the demographic variables. Controls 
were collected at the Institutes of Neuropathology, Heidelberg Uni-
versity, and University of Bonn, and their clinical records were col-
lected from their relatives and general practitioners. All assess-
ments and postmortem evaluations and procedures had been ap-
proved by the Ethics Committee of the Faculty of Medicine of 
Heidelberg and Bonn Universities, Germany. All patients and con-
trols underwent thorough neuropathologic characterization in or-
der to rule out associated neurovascular or neurodegenerative dis-
orders, such as Alzheimer’s disease and multi-infarct dementia  [19, 
20] . The staging according to Braak was 2 or less for all subjects. 
Patients and normal comparison subjects had no history of alcohol, 
drug abuse, or severe physical illness, e.g. carcinoma. Normal com-
parison subjects had no history of psychiatric disorders.
 Postmortem brains were dissected in the midline of the hemi-
spheres. Tissue blocks were prepared from the DLPFC Brodmann 
Table 1. C haracteristics of postmortem samples from patients with schizophrenia and normal comparison
subjects
Characteristic Tissue from
patients with
schizophrenia
(n = 12)
Tissue from
normal control
subjects
(n = 13)
Total subjects 12 13
Male 6 11
Female 6 2
Age at death, years 67.17814.06 64.54813.58
Postmortem interval, h 20.00810.49 23.85823.12
pH 6.4280.35 6.6580.37
Age at onset, years 24.6087.36
Duration of disease, years 41.50811.70
Duration of hospitalization, years 25.10815.32
Duration of antipsychotic medication, years 35.0089.72
Last dose of antipsychotic medication in CPE, mg 590.938746.62
Cumulative dose (last 10 years) of antipsychotic medication CPE, kg 4.0783.09
T here were no statistically significant differences between age at time of death, PMI and brain pH. Schizo-
phrenia patients were characterized by duration of disease, duration of medication and medication (last dose) 
in CPE, as well as cumulative dose over the last 10 years in CPE.
Data are presented as n or mean 8 SD.
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area (BA) BA9 and BA46, the superior temporal cortex (BA22), 
the entorhinal cortex (BA28), the sensoric cortex (BA1–3), the 
hippocampus Cornu Ammonis (CA) CA4 and the mediodorsal 
nucleus of the thalamus from the right and left hemispheres, re-
spectively. Cortical regions entailed gray and white matter. Blocks 
were immediately snap-frozen in liquid nitrogen-cooled isopen-
tane and stored at –80  °  C. From these, 10-  m sections were cut in 
triplicate and collected on coated slides. All material was coded, 
and experiments carried out by researchers blind to diagnosis.
 In Situ Hybridization 
 In situ hybridization  [21] was performed on two sections of 
each brain region with [ 35 S]-UTP-labeled cRNA probes of the ree-
lin gene. Briefly, RNA from human cerebral cortex (RNeasy; Qia-
gen, Hilden, Germany) was reverse transcribed. After PCR am-
plification (Promega, Mannheim, Germany) with specific prim-
ers derived from reelin (bases 251–710 in Genbank NM 001917), 
the amplicons were subcloned into gGEM-T vector (Promega, 
Mannheim, Germany). Correct amplification and orientation 
were checked by commercial sequencing (MWG, Ebersberg, Ger-
many). Linearized plasmids were transcribed in vitro with Sp6 or 
T7-RNA polymerase (MBI-Fermentas, St Leon Roth, Germany). 
Efficiency of incorporation of radioactively labeled [ 35 S]-UTP was 
measured, and hybridizations with antisense and sense probes 
using a concentration of 10 7 cpm/ml were carried out. After sev-
eral washing steps including RNAse A digestion, slices were de-
hydrated and exposed to X-ray films (Biomax MR1 18  ! 24 cm) 
for 2–6 days.
 Image Analysis 
 Autoradiographic films were analyzed with a video camera 
(Sony XC ST 70) and the AIS software (Applied Information Sys-
tems, Chapel Hill, N.C., USA). Nonspecific signals were assessed 
separately for each section in the same regions. These readings 
were subtracted from gray values in the regions of interest (total 
binding) resulting in a semiquantitative determination of mRNA 
abundance. Gray value images of the coexposed  14 C calibration 
standards (Amersham, UK) were used to compute a calibration 
curve by nonlinear least squares fitting, which defined the rela-
tionship between gray values and concentration of radioactivity.
 Statistical Analysis 
 Statistical analyses were performed with PASW Statistics 18. 
All tests were two tailed. The level of significance was   = 0.05. 
Distributions for all dependent variables were examined in both 
groups using histograms and the Kolmogorov-Smirnov test on 
normality. Due to the small sample size, the power for the Kol-
mogorov-Smirnov test was not very high. However, the results 
suggest a normal distribution of the data and analysis by paramet-
ric tests.
 As initial analyses, in all regions stepwise linear regression 
analyses with independent variables age, postmortem interval 
(PMI) and gender were performed, followed by analyses of covari-
ance (ANCOVA) with factor diagnostic group and intervening 
variables that showed a significant influence in regression analy-
ses. In regions without significant intervening variables, one-way 
analyses of variance (ANOVA) with factor diagnostic group were 
calculated. In regions where significant diagnostic group effects 
were detected, correlations between dependent and intervening 
variables age, PMI, brain pH and disease duration were per-
formed using Pearson correlation coefficients. As there were ex-
treme values for medication doses in CPE, we calculated Spear-
man rank correlation for medication variables. Correlations
were computed separately for schizophrenia patients and – if 
present – for controls.
 This is an explorative study aimed at finding variables that 
may show differences in the expression of reelin-mRNA between 
schizophrenia patients and control subjects. If a Bonferroni ad-
justment of the error probability of first kind for the number of 
statistical tests was applied, no significant differences between 
schizophrenia patients and controls would remain. However, an 
adjustment of the error probability would decrease the test power 
to such an extent that the power of detecting existing mean dif-
ferences would be very low. Thus, the present results are present-
ed without error probability correction. Due to the explorative 
study design and the problems of multiple testing, these findings 
offer no conclusive evidence for a causal relationship. An inde-
pendent larger sample has to be analyzed in an effort to confirm 
the positive findings of this study.
 Results 
 Schizophrenia patients did not differ from controls in 
terms of age (F = 0.3, d.f. = 1, 23; p = 0.62), pH (F = 0.5, 
d.f. = 1, 20; p = 0.68), PMI (F = 0.2, d.f. = 1, 23; p = 0.69) 
or gender (  2 = 3.44, d.f. = 1; p = 0.064) compared to con-
trols. Stepwise linear regression analyses showed a sig-
nificant influence of PMI on the gray matter of BA9, left 
side (p = 0.019), and BA46 [gray matter, left side (p = 
0.032), white matter, right side (p = 0.022), gray matter, 
right side (p = 0.005)], and on age in BA46, gray matter, 
left side (p = 0.021) and in the sensomotoric cortex BA1–
3, gray matter, left side (p = 0.024). Descriptives for spe-
cific bindings in the analyzed regions are shown in  ta-
ble 2 . Using ANOVA, we detected a decreased expression 
of 29.1% (F = 7.6; d.f. = 1, 9; p = 0.022) on the white matter 
of the left BA9 of schizophrenia patients compared to the 
control group. From ANCOVA (factor diagnosis, covari-
ate PMI) intending to adjust the analysis on diagnostic 
effects for this intervening variable, the decreased reelin-
mRNA expression in schizophrenic patients was signifi-
cant in the gray matter (–13.6%) of the left prefrontal cor-
tex, BA9 (F = 9.6, d.f. = 1, 15; p = 0.007;  fig. 1 ). In all oth-
er gray and white matter regions [the middle frontal 
cortex (BA46), the superior temporal cortex (BA22), the 
entorhinal cortex (BA28), hippocampal CA4, the sensor-
ic cortex (BA1–3), and the mediodorsal nucleus of the 
thalamus], we did not find statistically significant diag-
nostic group differences in the expression of reelin ( ta-
ble 2 ).
 The number of female subjects in the control sample 
was very small. However, for all regions, we have per-
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formed linear stepwise regression analyses with indepen-
dent variables gender, age and PMI, and there was not any 
significant predictive gender influence. In line with this 
result, there were no significant gender effects in all re-
gions when comparing the data of all male and female 
subjects with one-way ANOVA. When performing group 
comparisons adjusted for gender [ANOVA (group  ! 
gender) or ANCOVA (group  ! gender, covariate PMI)], 
respectively, we still revealed a significantly decreased ex-
pression in the white matter of the left BA9 in schizophre-
nia patients of both genders (male: schizophrenia vs. con-
trols: –14.1%, female: schizophrenia vs. controls: –58.9%, 
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 Fig. 1. Scatter plots of significant results 
(expression of reelin) in the gray and white 
matter of BA9. 
Table 2. D escriptive statistics for specific bindings in the analyzed brain regions in schizophrenic patients and controls
Region Left hemisphere R ight hemisphere
control schizophrenia cont rol schizophrenia
BA9 prefrontal cortex (white matter) 2,5268463 1,7928404* 2,046813 2,2378276
BA9 prefrontal cortex (gray matter) 1,4278321 1,2328191** 1,2908362 1,3988140
BA46 middle frontal cortex (white matter) 2,50081,216 2,2418585 2,4088985 2,4948759
BA46 middle frontal cortex (gray matter) 1,4068630 1,4898347 1,4498468 1,4928417
BA22 superior temporal cortex (white matter) 2,22481,113 2,0458769 2,49181,428 2,0768497
BA22 superior temporal cortex (gray matter) 1,4148437 1,4478390 1,5038699 1,4238245
BA1–3 sensoric cortex (white matter) 1,9048226 2,38281,525 1,7708316 2,1388671
BA1–3 sensoric cortex (gray matter) 1,3718243 1,6208467 1,3298336 1,5178331
Hippocampus (CA4) 1,6808376 1,8328500 1,4048233 1,7498313
BA28 entorhinal cortex (white matter) 1,8898426 1,8608583 1,8868551 2,1188645
BA28 entorhinal cortex (gray matter) 1,2138244 1,1698328 1,1498262 1,3558442
Mediodorsal nucleus of the thalamus 2,1158510 1,9858829 1,9758352 1,9448643
Dat a are given in Bq/mg brain tissue and are presented as mean 8 SD. There was a significant difference in the left white matter 
(p = 0.022) and gray matter of BA9 (p = 0.007) between schizophrenia patients and controls. * p = 0.022, ** p = 0.007.
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factor diagnosis: F = 40.8, d.f. = 1, 7; p  ! 0.0005) as well 
as a decreased expression in the gray matter of the left 
BA9 in schizophrenia patients of both genders (male: 
schizophrenia vs. controls: –12.4%, female: schizophre-
nia vs. controls: –9.9%, factor diagnosis: F = 9.0, d.f. = 1, 
13; p = 0.010).
 In controls, but not in schizophrenia patients, there 
was a significant negative correlation between PMI and 
reelin expression (r = –0.93, d.f. = 5; p = 0.003) in the left 
gray matter of BA9. In this region in patients, the last dose 
of antipsychotics in CPE showed a significant influence 
on specific binding of reelin (rho = 0.66, d.f. = 9; p = 
0.026).
 Discussion 
 In this study in schizophrenia patients, we detected 
decreased expression exclusively in the gray and white 
matter of the DLPFC (BA9), but not in other cortical or 
subcortical brain regions. Thus, we extended previous re-
sults showing decreased reelin expression in the frontal 
cortex in schizophrenia  [8, 11–13] , but we could not con-
firm decreased expression in temporal cortex and hippo-
campus  [8] . However, in these regions we investigated 
specific regions (BA22, CA4), and in other BAs decreased 
expression may be detected. In addition, we used in situ 
hybridization in specific gray and white matter subre-
gions, allowing more detailed analysis than RT-PCR in 
tissue blocks composed of different gray and white matter 
compartments. However, to verify quantitative measure-
ments, results should be confirmed by real-time PCR and 
Western blotting on the protein level.
 The PMI may influence mRNA integrity, and in our 
study, using regression and correlation analysis, we de-
tected an influence of PMI on reelin expression in the 
gray matter of BA9. However, the correlation was signifi-
cantly negative in controls, not in schizophrenia patients, 
and ANCOVA with PMI as intervening variable showed 
significant differences in gray matter. Since all patients 
had been treated with antipsychotics until death, medica-
tion may have influenced our results. However, we de-
tected a positive correlation between last dosage in CPE 
and reelin expression in the gray matter of BA9, allowing 
the assumption that decreased reelin levels may not be 
related to higher antipsychotic doses and thus excluding 
effects of dosage in CPE on reelin expression. Some of our 
patients had been treated with clozapine, which has been 
shown to activate DNA demethylation of the reelin pro-
moter in the frontal cortex of mice, suggesting an influ-
ence on gene expression  [22] . However, the frontal cortex 
of mice belongs to the motor cortex and is not comparable 
to human prefrontal cortex. Additionally, these mice 
were pretreated with  L -methionine to hypermethylate 
promoters. Effects of antipsychotics should be assessed in 
validated animal models for risk factors of schizophrenia.
 A further limitation is the small number of females in 
the control sample (only 2). Since genetic evidence sug-
gests reelin-associated effects only in females  [2–4] , this 
bias could make a difference. However, in our statistical 
analysis, we did not detect effects of gender, and epige-
netic mechanisms may also decrease reelin expression in 
male patients  [5, 6] . Hence, our results should be con-
firmed in a larger sample including more females.
 Our results confirm previous studies showing in-
creased epigenetic promoter hypermethylation in the 
prefrontal cortex of schizophrenia patients, which may 
lead to decreased gene expression  [5, 6] . Moreover, reelin 
expression was associated with decreased expression of 
synaptic proteins, supporting the role of reelin in dis-
turbed synaptic plasticity in schizophrenia  [15, 16] . In an-
imal studies, a deficit in the reelin gene is associated with 
a failure of neuroblasts to penetrate the subplate, result-
ing in disturbances of neuronal migration  [23] . In schizo-
phrenia, abnormal positioning of neurons during neuro-
nal migration has been shown and related to neurodevel-
opmental disturbances in the pathophysiology of the 
disease  [24, 25] . Apart from the fact that involvement of 
a mutation of the reelin gene has not consistently been 
reported in schizophrenia  [7] , an association of a reelin 
risk allele with working memory dysfunction and more 
severe positive and negative symptoms has been shown 
in large cohorts of schizophrenia patients  [26, 27] . There-
fore, reelin may be considered as a modifier gene in an 
interplay with genetic and environmental, epigenetic
factors in schizophrenia. Further postmortem studies 
should relate genetic and epigenetic factors to reelin ex-
pression in the DLPFC.
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